The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

[1]  T. Dick,et al.  Tuberculosis drug discovery: issues, gaps and the way forward. , 2009 .

[2]  JoAnne L. Flynn,et al.  Quantitative Comparison of Active and Latent Tuberculosis in the Cynomolgus Macaque Model , 2009, Infection and Immunity.

[3]  Robert J Wilkinson,et al.  Eliminating latent tuberculosis. , 2009, Trends in microbiology.

[4]  J. Christian J. Ray,et al.  Synergy between Individual TNF-Dependent Functions Determines Granuloma Performance for Controlling Mycobacterium tuberculosis Infection1 , 2009, The Journal of Immunology.

[5]  Alimuddin Zumla,et al.  Biomarkers for tuberculosis disease activity, cure, and relapse. , 2009, The Lancet. Infectious diseases.

[6]  Sabine Ehrt,et al.  Improved tetracycline repressors for gene silencing in mycobacteria , 2009, Nucleic acids research.

[7]  P. Selzer.  Antiparasitic and antibacterial drug discovery : from molecular targets to drug candidates , 2009 .

[8]  Y. Manabe,et al.  Tuberculosis genes expressed during persistence and reactivation in the resistant rabbit model. , 2009, Tuberculosis.

[9]  M. Daly,et al.  Multigenic control of tuberculosis resistance: analysis of a QTL on mouse chromosome 7 and its synergism with sst1 , 2009, Genes and Immunity.

[10]  W. Bishai,et al.  Role of the dosR-dosS Two-Component Regulatory System in Mycobacterium tuberculosis Virulence in Three Animal Models , 2008, Infection and Immunity.

[11]  Mark J. Schreiber,et al.  Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results. , 2008, Bioorganic & medicinal chemistry letters.

[12]  Pilho Kim,et al.  PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release , 2008, Science.

[13]  J. Collins,et al.  Mistranslation of Membrane Proteins and Two-Component System Activation Trigger Antibiotic-Mediated Cell Death , 2008, Cell.

[14]  S. Booker.  Faculty Opinions recommendation of Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. , 2008 .

[15]  Thomas Dick,et al.  The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis , 2008, Proceedings of the National Academy of Sciences.

[16]  Madhukar Pai,et al.  Systematic Review: T-Cellbased Assays for the Diagnosis of Latent Tuberculosis Infection: An Update , 2008, Annals of Internal Medicine.

[17]  K. Higuchi,et al.  Interferon‐γ responses after isoniazid chemotherapy for latent tuberculosis , 2008, Respirology.

[18]  W. Bishai,et al.  The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. , 2008, Tuberculosis.

[19]  C. Senner,et al.  Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum , 2008, PLoS medicine.

[20]  James A. Raleigh,et al.  Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates , 2008, Infection and Immunity.

[21]  Tige R. Rustad,et al.  The Enduring Hypoxic Response of Mycobacterium tuberculosis , 2008, PloS one.

[22]  Philip D. Butcher,et al.  Probing Host Pathogen Cross-Talk by Transcriptional Profiling of Both Mycobacterium tuberculosis and Infected Human Dendritic Cells and Macrophages , 2008, PloS one.

[23]  T. Shim,et al.  Evaluation of Therapeutic Response of Tuberculoma Using F-18 FDG Positron Emission Tomography , 2008, Clinical nuclear medicine.

[24]  Christopher Dye,et al.  Eliminating human tuberculosis in the twenty-first century , 2008, Journal of The Royal Society Interface.

[25]  Chris Abell,et al.  Fragment-based approaches to enzyme inhibition. , 2007, Current opinion in biotechnology.

[26]  W. Hillen,et al.  In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice , 2007, Nature Medicine.

[27]  D. Russell,et al.  Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. , 2007, Cell host & microbe.

[28]  G. Terstappen,et al.  Target deconvolution strategies in drug discovery , 2007, Nature Reviews Drug Discovery.

[29]  R. Lange,et al.  The targets of currently used antibacterial agents: lessons for drug discovery. , 2007, Current pharmaceutical design.

[30]  J. Collins,et al.  A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics , 2007, Cell.

[31]  John Chan,et al.  Differences in Reactivation of Tuberculosis Induced from Anti-TNF Treatments Are Based on Bioavailability in Granulomatous Tissue , 2007, PLoS Comput. Biol..

[32]  S. Klamt,et al.  GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism , 2007, Genome Biology.

[33]  S. Johnston,et al.  Mycobacterial Bacilli Are Metabolically Active during Chronic Tuberculosis in Murine Lungs: Insights from Genome-Wide Transcriptional Profiling , 2007, Journal of bacteriology.

[34]  J. Mckinney,et al.  Microbial phenotypic heterogeneity and antibiotic tolerance. , 2007, Current opinion in microbiology.

[35]  L. Silver.  Multi-targeting by monotherapeutic antibacterials , 2007, Nature Reviews Drug Discovery.

[36]  G. Ippolito,et al.  Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study , 2007, Respiratory research.

[37]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[38]  D. Kirschner,et al.  Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. , 2006, The Journal of Immunology.

[39]  J. Deeks,et al.  Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. , 2006, American journal of respiratory and critical care medicine.

[40]  R. Sauermann,et al.  Principles of Antibiotic Penetration into Abscess Fluid , 2006, Pharmacology.

[41]  A. Myers,et al.  Early Events in Mycobacterium tuberculosis Infection in Cynomolgus Macaques , 2006, Infection and Immunity.

[42]  E. Muñoz-Elías,et al.  Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence , 2006, Molecular microbiology.

[43]  R. Wilkinson,et al.  Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. , 2006, The Journal of infectious diseases.

[44]  D. Eisenberg,et al.  Unique Transcriptome Signature of Mycobacterium tuberculosis in Pulmonary Tuberculosis , 2006, Infection and Immunity.

[45]  J. Norton,et al.  Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Dannenberg.  Pathogenesis of Human Pulmonary Tuberculosis: Insights from the Rabbit Model , 2006 .

[47]  E. Rubin,et al.  Differential Antibiotic Susceptibilities of Starved Mycobacterium tuberculosis Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[48]  J. Kettenbach,et al.  Antibiotic Abscess Penetration: Fosfomycin Levels Measured in Pus and Simulated Concentration-Time Profiles , 2005, Antimicrobial Agents and Chemotherapy.

[49]  Nagasuma R. Chandra,et al.  Flux Balance Analysis of Mycolic Acid Pathway: Targets for Anti-Tubercular Drugs , 2005, PLoS Comput. Biol..

[50]  M. Reed,et al.  Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. , 2005, The Journal of infectious diseases.

[51]  C. F. von Reyn,et al.  High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  A. Garza,et al.  The relA Homolog of Mycobacterium smegmatis Affects Cell Appearance, Viability, and Gene Expression , 2005, Journal of bacteriology.

[53]  P. Venkatesan,et al.  Bactericidal Action of Gatifloxacin, Rifampin, and Isoniazid on Logarithmic- and Stationary-Phase Cultures of Mycobacterium tuberculosis , 2005, Antimicrobial Agents and Chemotherapy.

[54]  Pam Sonnenberg,et al.  How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. , 2005, The Journal of infectious diseases.

[55]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[56]  V. Mischenko,et al.  Direct comparison of low-dose and Cornell-like models of chronic and reactivation tuberculosis in genetically susceptible I/St and resistant B6 mice. , 2005, Tuberculosis.

[57]  T. Myers,et al.  The Transcriptional Responses of Mycobacterium tuberculosis to Inhibitors of Metabolism , 2004, Journal of Biological Chemistry.

[58]  Byron F. Brehm-Stecher,et al.  Single-Cell Microbiology: Tools, Technologies, and Applications , 2004, Microbiology and Molecular Biology Reviews.

[59]  Georg E. Schulz,et al.  The Structure of a Mycobacterial Outer-Membrane Channel , 2004, Science.

[60]  D. Saini,et al.  Disruption of response regulator gene, devR, leads to attenuation in virulence of Mycobacterium tuberculosis. , 2004, FEMS microbiology letters.

[61]  Gilla Kaplan,et al.  Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Christopher M. Sassetti,et al.  Genetic requirements for mycobacterial survival during infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[63]  JoAnne L. Flynn,et al.  Experimental Mycobacterium tuberculosis Infection of Cynomolgus Macaques Closely Resembles the Various Manifestations of Human M. tuberculosis Infection , 2003, Infection and Immunity.

[64]  Tsuneo Suzuki,et al.  Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. , 2003, Chest.

[65]  Dirk Schnappinger,et al.  Inhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program , 2003, The Journal of experimental medicine.

[66]  Chi-Ming Lee,et al.  Intense uptake of [F-18]-fluoro-2 deoxy-d-glucose in active pulmonary tuberculosis , 2003, Annals of nuclear medicine.

[67]  E. Rubin,et al.  Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.

[68]  C. Walsh.  Antibiotics: Actions, Origins, Resistance , 2003 .

[69]  G. Schoolnik,et al.  Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: Insights into the phagosomal environment JOURNAL OF EXPERIMENTAL MEDICINE , 2003 .

[70]  J. Betts,et al.  In Situ Detection of Mycobacterium tuberculosis Transcripts in Human Lung Granulomas Reveals Differential Gene Expression in Necrotic Lesions , 2002, Infection and Immunity.

[71]  Thomas M. Shinnick,et al.  Microarray Analysis of the Mycobacterium tuberculosis Transcriptional Response to the Acidic Conditions Found in Phagosomes , 2002, Journal of bacteriology.

[72]  Gary K. Schoolnik,et al.  ideR, an Essential Gene in Mycobacterium tuberculosis: Role of IdeR in Iron-Dependent Gene Expression, Iron Metabolism, and Oxidative Stress Response , 2002, Infection and Immunity.

[73]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[74]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[75]  James C. Sacchettini,et al.  Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase , 2000, Nature.

[76]  J. Goo,et al.  Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. , 2000, Radiology.

[77]  I. Orme,et al.  Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. , 1997, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[78]  J. Liu,et al.  Mycolic Acid Structure Determines the Fluidity of the Mycobacterial Cell Wall* , 1996, The Journal of Biological Chemistry.

[79]  P. Venkatesan,et al.  Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis , 1996, Antimicrobial agents and chemotherapy.

[80]  W. Stead.  Management of Health Care Workers after Inadvertent Exposure to Tuberculosis: A Guide for the Use of Preventive Therapy , 1995, Annals of Internal Medicine.

[81]  L. Wayne,et al.  Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis , 1994, Antimicrobial Agents and Chemotherapy.

[82]  H. Nikaido,et al.  Permeability of the mycobacterial cell wall. , 1991, Research in microbiology.

[83]  J. Grange.  The mycobacteria: a sourcebook , 1985 .

[84]  Kislitsyna Na.  Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients , 1985 .

[85]  N. A. Kislitsyna.  [Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients]. , 1985, Problemy tuberkuleza.

[86]  G. Kubica,et al.  The Mycobacteria : a sourcebook , 1984 .

[87]  Kislitsyna Na,et al.  Rifampicin and isoniazid concentration in the blood and resected lungs in tuberculosis with combined use of the preparations , 1980 .

[88]  N. A. Kislitsyna,et al.  [Rifampicin and isoniazid concentration in the blood and resected lungs in tuberculosis with combined use of the preparations]. , 1980, Problemy tuberkuleza.

[89]  D. Snider,et al.  Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. , 2015, The American review of respiratory disease.

[90]  S. Robbins,et al.  Pathologic basis of disease , 1974 .

[91]  R. Parrot,et al.  [Rifomycin levels in the lung and tuberculous lesions in man]. , 1969, Acta tuberculosea et pneumologica Belgica.

[92]  Veening Gj.  Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. , 1968 .

[93]  G. Veening.  Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. , 1968, Bulletin of the International Union against Tuberculosis.

[94]  S. Ferebee,et al.  A CONTROLLED TRIAL OF ISONIAZID PROPHYLAXIS IN MENTAL INSTITUTIONS. , 1963, The American review of respiratory disease.

[95]  S. Ferebee,et al.  Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. , 2015, The American review of respiratory disease.

[96]  W. Segal,et al.  Pathogenic and immunogenic differentiation of Mycobacterium tuberculosis grown in vitro and in vivo. , 1957, American review of tuberculosis.

[97]  W. Segal,et al.  BIOCHEMICAL DIFFERENTIATION OF MYCOBACTERIUM TUBERCULOSIS GROWN IN VIVO AND IN VITRO , 1956, Journal of bacteriology.

[98]  H. M. Vandiviere,et al.  THE TREATED PULMONARY LESION AND ITS TUBERCLE BACILLUS.*: II. THE DEATH AND RESURRECTION , 1956, The American journal of the medical sciences.